TheNote
Nucala (mepolizumab) delivers ... Note
GooglePlay AppStore
GSK press releases

Nucala (mepolizumab) delivers clinically meaningful and statistically significant reduction in COPD exacerbations, with positive MATINEE trial results published in New England Journal of Medicine

21% reduction in annualised rate of moderate/severe exacerbations in a wide COPD population
https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-delivers-clinically-meaningful-and-statistically-significant-reduction-in-copd-exacerbations-with-positive-matinee-trial-results-published-in-nejm/ gsk.com
RSS Hunter RSS Hunter • Apr 30, 2025

Cookies help us deliver our Services. By using our Services or clicking I agree, you agree to our use of cookies .